[Clinical study on cinobufotalin in treating chronic hepatitis B virus carriers].
In a preliminary study, carriers of hepatitis B virus were treated with Cinobufotalin, a preparation from toad, for 1-3 course of treatment. Results indicated that negative conversion rate was markedly higher in the treated groups (21.09%, 38.89%, 63.64% and 50%) than that of control groups (2.1%, 10.87%, 33.33% and 7.7% P < 0.001). By the end of treatment, positive conversion rate of anti-HBs and anti-HBe were also markedly higher in the former (19.29% and 23.45%) than that in the latter (4.26% and 7.14% P < 0.001). During the follow-up of 3-6 months, the positive rate of HBeAg in treated group (50%) raised as compared with the control group (20% P = 0.08). The results indicated that Cinobufotalin had a significant effect in inhibiting the replication of HBV.
Xu
X T
XT
Linyi Medical School.
D002018:Bufanolides / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy*; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006801:Humans; D008297:Male; D008419:Materia Medica / Q000627:therapeutic use*
D002018:Bufanolides; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D008419:Materia Medica; C063451:cinobufotalin